NCT00865449

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.

Conditions

• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	spironolactone	25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
DRUG	Placebo	Placebo, given daily for 6 months to Peritoneal Dialysis Patients

Timeline

• Start date: 2008-07-01
• Primary completion: 2011-12-01
• Completion: 2012-03-01
• First posted: 2009-03-19
• Last updated: 2012-10-25

Locations

1 site across 1 country: Mexico